Literature DB >> 25878332

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.

Jacob P Laubach1, Paul G Richardson2.   

Abstract

CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25878332     DOI： 10.1158/1078-0432.CCR-14-3190

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  17 in total

1.  The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Authors:  Alba Matas-Céspedes; Anna Vidal-Crespo; Vanina Rodriguez; Neus Villamor; Julio Delgado; Eva Giné; Heleia Roca-Ho; Pablo Menéndez; Elías Campo; Armando López-Guillermo; Dolors Colomer; Gaël Roué; Adrian Wiestner; Paul W H I Parren; Parul Doshi; Jeroen Lammerts van Bueren; Patricia Pérez-Galán
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

2.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Authors:  Anna Oberle; Anna Brandt; Malik Alawi; Claudia Langebrake; Snjezana Janjetovic; Christine Wolschke; Kerstin Schütze; Peter Bannas; Nicolaus Kröger; Friedrich Koch-Nolte; Carsten Bokemeyer; Mascha Binder
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

4.  The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Authors:  Tatiana Pazina; Ashley M James; Alexander W MacFarlane; Natalie A Bezman; Karla A Henning; Christine Bee; Robert F Graziano; Michael D Robbins; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

5.  Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.

Authors:  Kenshi Suzuki; Chang-Ki Min; Kihyun Kim; Je-Jung Lee; Hirohiko Shibayama; Po-Shen Ko; Shang-Yi Huang; Sin-Syue Li; Bifeng Ding; Monica Khurana; Shinsuke Iida
Journal:  Int J Hematol       Date:  2021-08-19       Impact factor: 2.490

6.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Authors:  Michael Boyiadzis; Michael R Bishop; Rafat Abonour; Kenneth C Anderson; Stephen M Ansell; David Avigan; Lisa Barbarotta; Austin John Barrett; Koen Van Besien; P Leif Bergsagel; Ivan Borrello; Joshua Brody; Jill Brufsky; Mitchell Cairo; Ajai Chari; Adam Cohen; Jorge Cortes; Stephen J Forman; Jonathan W Friedberg; Ephraim J Fuchs; Steven D Gore; Sundar Jagannath; Brad S Kahl; Justin Kline; James N Kochenderfer; Larry W Kwak; Ronald Levy; Marcos de Lima; Mark R Litzow; Anuj Mahindra; Jeffrey Miller; Nikhil C Munshi; Robert Z Orlowski; John M Pagel; David L Porter; Stephen J Russell; Karl Schwartz; Margaret A Shipp; David Siegel; Richard M Stone; Martin S Tallman; John M Timmerman; Frits Van Rhee; Edmund K Waller; Ann Welsh; Michael Werner; Peter H Wiernik; Madhav V Dhodapkar
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

7.  Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo.

Authors:  William Fumey; Julia Koenigsdorf; Valentin Kunick; Stephan Menzel; Kerstin Schütze; Mandy Unger; Levin Schriewer; Friedrich Haag; Gerhard Adam; Anna Oberle; Mascha Binder; Ralf Fliegert; Andreas Guse; Yong Juan Zhao; Hon Cheung Lee; Fabio Malavasi; Fernando Goldbaum; Rob van Hegelsom; Catelijne Stortelers; Peter Bannas; Friedrich Koch-Nolte
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

8.  Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Authors:  Paul G Richardson; William I Bensinger; Carol Ann Huff; Caitlin L Costello; Nikoletta Lendvai; Jesus G Berdeja; Larry D Anderson; David S Siegel; Daniel Lebovic; Sundar Jagannath; Jacob P Laubach; Keith E Stockerl-Goldstein; Long Kwei; Fong Clow; Laurence Elias; Zeena Salman; Thorsten Graef; Elizabeth Bilotti; Ravi Vij
Journal:  Br J Haematol       Date:  2018-02-13       Impact factor: 6.998

Review 9.  Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.

Authors:  S Lonial; B Durie; A Palumbo; J San-Miguel
Journal:  Leukemia       Date:  2015-08-12       Impact factor: 11.528

10.  Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.

Authors:  Muhammad Husnain; Sandra Kurtin; Nikki Barkett; Irbaz Bin Riaz; Amit Agarwal
Journal:  Case Rep Oncol Med       Date:  2016-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.